Systemic inflammation and risk of multiple sclerosis: A presymptomatic case-control studyShow others and affiliations
2022 (English)In: Multiple Sclerosis Journal, Experimental, Translational and Clinical, E-ISSN 2055-2173, Vol. 8, no 4, article id 20552173221139768Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: C-reactive protein (CRP) is a marker of systemic inflammation. Increased levels of CRP in young persons have been suggested to decrease the risk of multiple sclerosis (MS). OBJECTIVES: To assess CRP as a risk factor for MS. METHODS: Levels of CRP were measured with a high-sensitive immunoassay in biobank samples from 837 individuals who later developed MS and 984 matched controls. The risk of developing MS was analysed by conditional logistic regression on z-scored CRP values. RESULTS: Levels of CRP were not associated with MS risk. CONCLUSIONS: We found no association between CRP levels and risk of MS development.
Place, publisher, year, edition, pages
Sage Publications, 2022. Vol. 8, no 4, article id 20552173221139768
Keywords [en]
C-reactive protein, Case-control studies, multiple sclerosis, systemic inflammation
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:oru:diva-102534DOI: 10.1177/20552173221139768ISI: 000927944400001PubMedID: 36440320Scopus ID: 2-s2.0-85142702455OAI: oai:DiVA.org:oru-102534DiVA, id: diva2:1716293
2022-12-052022-12-052023-12-07Bibliographically approved